Global “Biotechnology Contract Manufacturing Market” was expected to be worth $16.28 Bn in 2023 and is poised to reach $31.05 Bn by 2031, at a significant CAGR of 8.68% from 2024 to 2031.
Global “Biotechnology Contract Manufacturing Market” was expected to be worth $16.28 Bn in 2023 and is poised to reach $31.05 Bn by 2031, at a significant CAGR of 8.68% from 2024 to 2031.
Market Analysis:
The biotechnology contract manufacturing market encompasses a wide range of services, including cell line development, upstream and downstream processing, formulation, fill-finish, and packaging.
The increasing demand for biopharmaceuticals and biologics, rising investment in research and development, advancements in bioprocessing technologies, outsourcing of manufacturing activities by pharmaceutical and biotechnology companies, and the emergence of novel therapeutics is expected to generate noteworthy market growth during the forecast period.
Download Free Report Sample Pages: https://www.insightaceanalytic.com/request-sample/2067
Latest Drivers Restraint and Opportunities Market Snapshot:
Key Factors Influencing The Global Biotechnology Contract Manufacturing Market Are:
- The increasing use of biologics in a wide range of therapeutic areas, the growing demand for personalized medicine, and the emergence of new manufacturing technologies that enable more efficient and cost-effective production of biopharmaceuticals are driving market growth.
- Pharmaceutical companies can benefit from cost savings and efficiency gains associated with outsourcing, which allows them to drive innovation in the biopharmaceutical sector.
- Biotechnology Contract Manufacturing leverages ongoing advanced technologies to provide researchers with access to high-quality biotechnology and associated data for various research studies.
The following are the primary obstacles to the Biotechnology Contract Manufacturing Market’s expansion:
- The increasing complexity of biologics, the need for specialized facilities and equipment, and regulatory compliance restrain the market.
- Another challenge manufacturers encounter is the risk of intellectual property theft. As contract manufacturers often work with multiple clients, confidential information could be shared or stolen.
- High capital investment and operational expenses can limit the profitability of the Biotechnology Contract Manufacturing Market and discourage new entrants.
Future Expansion Opportunities For The Global Biotechnology Contract Manufacturing Market Include:
- The demand for biopharmaceuticals, which are typically more complex and difficult to manufacture than traditional chemical drugs, is increasing. As a result, many pharmaceutical companies are turning to contract manufacturers to help them produce these drugs at scale, which is expected to create lucrative opportunities in the market.
- Pharmaceutical companies are looking to outsource their manufacturing operations to reduce costs, increase efficiency, and focus on their core competencies.
- The global biotechnology contract manufacturing market is poised for expansion, driven by increasing demand for biotechnology in research and development activities worldwide.
Key Industry Insights & Findings from the Report:
- The increasing use of biologics in a wide range of therapeutic areas is expected to drive the market growth of the Biotechnology Contract Manufacturing market.
- The increasing demand for Personalized Medicine and Increasing acceptance of biosimilars is estimated to further drive industry growth.
- North America ruled the market and accounted for a revenue share of global revenue in 2023.
- One significant concern restraining industry growth is the high capital investment and operational expenses of the Biotechnology Contract Manufacturing Market.
List of Prominent Players in the Biotechnology Contract Manufacturing Market:
- Lonza (Switzerland)
- Samsung Biologics (South Korea)
- Thermo Fisher Scientific, Inc. (US)
- Catalent, Inc. (US)
- JSR Corporation (Japan)
- WuXi Biologics (China)
- AbbVie, Inc. (US)
- Boehringer Ingelheim International GmbH (Germany)
- Eurofins Scientific (Luxembourg)
- GenScript Biotech Corporation (US)
- AGC, Inc. (Japan)
- FUJIFILM Holding Corporation (Japan)
- Merck KgaA (Germany)
- Stelis
- Recipharm Ab
- Emergent
- Shanghai Fosun Pharmaceutical Co., Ltd.
- Lotte Biologics
- Hepalink Group
- Curia Global, Inc.
- Jrs Pharma
- Minapharm Pharmaceuticals
- Rentschler Biopharma Se
- Avid Bioservices, Inc.
- Abzena Ltd.
- Polyplus Transfection
- Midas Pharma GMBH
- Mabplex International Co., Ltd.
- Asahi Kasei Corporation
Recent Developments:
- In June 2023, Cell and Gene Therapy Catapult has announced a technology licensing arrangement with Albumedix that will see the latter company’s latest technology used to improve viral vector manufacturing.
- In June 2023, Wuxi Biologics, which provides end-to-end solutions for discovering, developing, and manufacturing biologics, has announced an increase in capacity for drug requirements and drug products at its facility in Wuppertal, Germany.
- In March 2023, Samsung Biologics stated the formation of a fifth plant at its location in Incheon, South Korea, as part of a strategic expansion to meet rising market demand. After completion, the plant is planned to have a manufacturing capacity of 180,000 L. By investing KRW 1.9 trillion, the business will increase its overall site capacity to 784,000 L.
Biotechnology Contract Manufacturing Market Dynamics:
Market Drivers: Increasing Number of Biologics in Development
The rising number of biologics in development is a significant driver of the Biotechnology Contract Manufacturing Market. As biopharmaceutical companies increasingly focus on developing biologic drugs, they often need more in-house manufacturing capacity and expertise to produce these complex therapies efficiently. Consequently, they turn to contract manufacturing organizations (CMOs) for specialized biomanufacturing services.
The growing pipeline of biologics, including monoclonal antibodies, recombinant proteins, and cell and gene therapies, fuels demand for contract manufacturing services, driving market growth. CMOs play a crucial role in enabling biopharmaceutical companies to bring innovative biologic therapies to market efficiently and cost-effectively.
Challenges: High Manufacturing Cost Associated With Biotechnology Contract Manufacturing Market
The high manufacturing cost poses a significant challenge for the Biotechnology Contract Manufacturing Market. Biopharmaceutical manufacturing involves complex processes, stringent quality requirements, and specialized facilities, leading to substantial operational expenses.
Additionally, biologics often require advanced technologies and large-scale production, further driving up costs. Contract manufacturing organizations (CMOs) must invest in state-of-the-art infrastructure, skilled personnel, and regulatory compliance to meet industry standards, adding to the cost burden. As a result, biopharmaceutical companies face pricing pressures and profitability challenges when outsourcing manufacturing services. At the same time, CMOs must balance cost-efficiency with maintaining quality and compliance, impacting market competitiveness and profitability.
North America Is Expected To Grow With The Highest CAGR During The Forecast Period
The North America Biotechnology Contract Manufacturing Market is likely to register a significant revenue share and develop at a rapid CAGR in the near future. It is due to pharmaceutical companies in the region increasingly looking to outsource manufacturing to specialized providers. There is an increase in outsourcing manufacturing to reduce costs and increase efficiency in North America. Contract manufacturers can provide economies of scale that lead to lower costs for pharmaceutical companies.
The government has implemented different policies to promote the growth of the biopharmaceutical sector, including tax incentives, streamlined regulatory processes, and investments in infrastructure and research and development.
Segmentation of Biotechnology Contract Manufacturing Market-
By Service:
- Manufacturing
- Formulation and Fill-Finish
- Packaging and Labeling
- Other services
By Source Type:
- Mammalian Based
- Microbial Based
By Molecule Type:
- Monoclonal Antibodies
- Recombinant Protein
- Vaccine
- Insulin
- Growth factor
- Interferons
- Others
By Type
- Biologic Drug Substance Manufacturing
- Biologic Drug Product Manufacturing
By Scale of Operation:
- Clinical
- Commercial
By Therapeutic Area:
- Oncology
- Autoimmune Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Infectious Diseases
- Neurology
- Other Therapeutic Areas
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Talk with Experts Panel on the Biotechnology Contract Manufacturing Market Report @ https://calendly.com/insightaceanalytic/30min?month=2024-02
Call: North America +1 551 226 6109 Email: diana.dsouza@insightaceanalytics.com